Vasoreactivity and inhaled treprostinil response in interstitial lung disease pulmonary hypertension
Introduction Despite shared features with pulmonary arterial hypertension, acute vasoreactivity in pulmonary hypertension with interstitial lung disease (PH-ILD) is not well characterised, including its potential ability to predict therapeutic outcomes. We sought to determine whether acute vasoreact...
Saved in:
Main Authors: | Eileen M. Harder, Farbod N. Rahaghi, Jane A. Leopold, David M. Systrom, George R. Washko, Aaron B. Waxman |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2024-12-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/10/6/00201-2024.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Vasoreactive testing prevalence and characteristics in patients with idiopathic pulmonary arterial hypertension
by: Goncharova Natalia, et al.
Published: (2025-01-01) -
The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
by: Piotr Kędzierski, et al.
Published: (2025-01-01) -
Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
by: Ci Song, et al.
Published: (2022-06-01) -
Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population
by: Andrew E. Stine, et al.
Published: (2025-01-01) -
Derivation of a simple risk calculator for predicting clinical worsening in patients with pulmonary hypertension due to interstitial lung disease
by: K. El-Kersh, et al.
Published: (2025-02-01)